Colonial Trust’s Novartis NVS Stock Holding History

Colonial Trust’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$142K	Sell	903 -769	-46%	-$115K	0.02%	343
2026 Q1	$255K	Sell	1,672 -190	-10%	-$29.1K	0.03%	249
2025 Q4	$257K	Sell	1,862 -1,738	-48%	-$228K	0.03%	253
2025 Q3	$462K	Sell	3,600 -13	-0.4%	-$1.59K	0.06%	194
2025 Q2	$437K	Buy	3,613 +21	+0.6%	+$2.37K	0.06%	194
2025 Q1	$400K	Buy	3,592 +3	+0.1%	+$319	0.06%	197
2024 Q4	$349K	Buy	3,589 +615	+21%	+$65.6K	0.05%	216
2024 Q3	$342K	Sell	2,974 -89	-3%	-$10.1K	0.05%	220
2024 Q2	$326K	Sell	3,063 -84	-3%	-$8.43K	0.06%	201
2024 Q1	$304K	Buy	3,147 +20	+0.6%	+$2.05K	0.06%	213
2023 Q4	$316K	Hold	3,127	–	–	0.07%	198
2023 Q3	$319K	Sell	3,127 -60	-2%	-$6.09K	0.08%	170
2023 Q2	$322K	Sell	3,187 -20	-0.6%	-$2K	0.08%	171
2023 Q1	$295K	Sell	3,207 -256	-7%	-$22.4K	0.08%	182
2022 Q4	$314K	Hold	3,463	–	–	0.09%	163
2022 Q3	$263K	Buy	+3,463	New	+$287K	0.08%	170

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Colonial Trust's NVS Position: Q2 2026 in Review

Colonial Trust reduced its Novartis (NVS) stake by 46% in Q2 2026, selling an estimated $115K and leaving 903 shares worth $142K. The position accounts for 0.02% of the portfolio, ranked #343.

Colonial Trust first reported a position in NVS in Q3 2022 and has held it in 16 quarters since. The position peaked at $462K in Q3 2025. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Colonial Trust held 903 shares of Novartis worth $142K as of Q2 2026.
Colonial Trust sold 769 Novartis shares in Q2 2026, an estimated $115K.
Novartis made up 0.02% of Colonial Trust's portfolio in Q2 2026, its #343 holding.
Colonial Trust first reported a position in Novartis in Q3 2022 and has held it in 16 quarters since.
Colonial Trust's Novartis position peaked at $462K in Q3 2025.
1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Colonial Trust's 13F filing for Q2 2026, filed 11 Aug 2026.